Literature DB >> 25745902

The treatment of periprosthetic fractures.

Aaron Nauth1, Markku T Nousiainen, Richard Jenkinson, Jeremy Hall.   

Abstract

The management of periprosthetic fractures is an issue of increasing importance for orthopaedic surgeons. Because of the expanding indications for total joint arthroplasty (TJA) and an aging population with increasingly active lifestyles, the incidence of primary and revision TJA is increasing, and there is a corresponding increase in the prevalence of periprosthetic fractures about a TJA. The management of these fractures is often complex because of issues with obtaining fixation around implants, dealing with osteopenic bone or compromised bone stock, and the potential need for revising loose TJA components. In addition, these injuries frequently occur in frail, elderly patients, and the literature has demonstrated that both morbidity and mortality in these patients is similar to that of the geriatric hip fracture population. As such, the early restoration of function and ambulation is critical in patients with these injuries, and effective surgical strategies to achieve these goals are essential.

Entities:  

Mesh:

Year:  2015        PMID: 25745902

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  3 in total

1.  The Biological Metallic versus Metallic Solution in Treating Periprosthetic Femoral Fractures: Outcome Assessment.

Authors:  Serafino Carta; Mattia Fortina; Alberto Riva; Luigi Meccariello; Enrico Manzi; Antonio Di Giovanni; Paolo Ferrata
Journal:  Adv Med       Date:  2016-11-20

2.  An Unusual Complication after Infected Total Knee Arthroplasty.

Authors:  Giuseppe Solarino; Giuseppe Maccagnano; Michele Saracino; Biagio Moretti
Journal:  Joints       Date:  2019-10-11

3.  Periprosthetic femoral fractures in Total Hip Arthroplasty (THA): a comparison between osteosynthesis and revision in a retrospective cohort study.

Authors:  Gianluca Scalici; Debora Boncinelli; Luigi Zanna; Roberto Buzzi; Laura Antonucci; Fabrizio Di Maida; Pietro De Biase
Journal:  BMC Musculoskelet Disord       Date:  2022-03-03       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.